SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List
13. Dezember 2024 10:00 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics ranked first on the Crain’s Cleveland Business Fast 50 list of rapidly growing, privately held companies in Northeast Ohio.
SPR® Therapeutics Debuts New SPRINT® PNS Data for Low Back, Shoulder, Knee, and Headache at the 23rd Annual ASRA Pain Medicine Meeting
21. November 2024 08:00 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics announced eight scientific abstracts that will be presented at the upcoming ASRA Pain Medicine Meeting
Ben Austin, CFO and COO of SPR® Therapeutics, Named to Crain’s Cleveland Business 40 Under 40 List
18. November 2024 11:20 ET
|
SPR Therapeutics, Inc.
Ben Austin, CFO and COO of SPR® Therapeutics, Named
to Crain’s Cleveland Business 40 Under 40 List.
SPRINT® PNS Demonstrates Robust Results in Addressing Chronic Shoulder Pain
06. August 2024 09:00 ET
|
SPR Therapeutics, Inc.
A new real-world retrospective analysis of patients who received 60-day PNS for chronic shoulder pain has been published in Pain Management.
SPR® Therapeutics Unveils Long-term Data on SPRINT® PNS and Initial MONARCH™ Trial Update
15. Juli 2024 09:05 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics announced the presentation of five abstracts at the ASPN Annual Conference including four-year data on SPRINT PNS.
SPR® Therapeutics Recognized as a Top Workplace in Northeast Ohio for the Third Year in a Row
23. Juni 2024 10:00 ET
|
SPR Therapeutics, Inc.
Medical Device Leader SPR Therapeutics again named a Top Workplace in Northeast Ohio
New Publication Reviewing Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets
11. Juni 2024 12:47 ET
|
SPR Therapeutics, Inc.
New Publication on Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets
UPDATE - SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee Pain
14. Mai 2024 18:33 ET
|
SPR Therapeutics, Inc.
Publication of study provides evidence of the impact of SPRINT PNS in relieving post-operative knee pain after total knee arthroplasty (TKA).
SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee Pain
13. Mai 2024 14:16 ET
|
SPR Therapeutics, Inc.
Publication of study provides evidence of the impact of SPRINT PNS in relieving post-operative knee pain after total knee arthroplasty (TKA).
SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System
01. Februar 2024 09:00 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics Announces $85 Million in Additional Funding to Advance Commercial Expansion of SPRINT PNS System.